LCM Genect

LCM Genect is an Italian company committed to the development of certificated molecular diagnosis, pharmacogenetics and liquid biopsy tests.

[LCM Genect @LCMGenect]

Join us at the #AMP EUROPE 2021!

LCM Genect Industry Symposium held by Dr. Maria Giulia Cangi and Dr. Lorenza Pecciarini will be focused on #genefusions in #cancer: a streamlined #molecularbiology approach.

#SaveTheDate: Wednesday 16th, 2:00-2:45 PM.

[LCM Genect @LCMGenect]

@CroAviano @LGerratana @uniud @puglisi_fabio Complimenti @LGerratana da tutto lo staff @LCMGenect

[LCM Genect @LCMGenect]

@AmoyDx Great job!

[LCM Genect @LCMGenect]

Great news!

[Amoy Diagnostics @AmoyDx]

AmoyDx Collaborates with #Amgen to Develop Companion #Diagnostics for China Market.
AmoyDx announced that it signed an agreement with Amgen to develop Companion Diagnostic tests supporting an investigational #molecule within Amgen’s oncology portfolio.

https://t.co/WI42gJdbgu

[LCM Genect @LCMGenect]

CerTest BioTec Coronavirus Test for Becton Dickinson System Gets CE Mark https://t.co/mKnhLDgj1O

[LCM Genect @LCMGenect]

Siamo orgogliosi di poter offrire le proprie competenze e soluzioni per affrontare #covid19.
Vi informiamo che siamo operativi nel pieno rispetto del decreto ministeriale e siamo in grado di mantenere tutti i servizi #coronavirusitalia #fightcoronavirus

[LCM Genect @LCMGenect]

#coronarvirusitalia Un dovere restare uniti @ConfindustriaDM #ImpreseResponsabili

[ConfindustriaDM @ConfindustriaDM]

#coronavirusitalia con l’Accordo di responsabilità di #ConfindustriaDM l’industria si unisce per la salute del Paese. Grazie alle nostre imprese firmatarie.

#ImpreseResponsabili

[LCM Genect @LCMGenect]

Biopsia liquida, accordo tra Lcm Genect e Exosomics https://t.co/EHfJcEL4yT via @AboutPharmaHPS

[LCM Genect @LCMGenect]

LA BIOPSIA LIQUIDA GUARDA AL FUTURO
@LCMGenect ed @exosomics_dx: quando l’innovazione made in Italy si unisce, la medicina di precisione supera i confini.
https://t.co/26Sgfjo4If #PrecisionMedicine #liquidbiopsy #madeInItaly

[CAPathologists @Pathologists]

With two inhibitors approved by the FDA for the treatment of NTRK-fusion-positive solid tumors, the next step is to determine whom to test and how. Read more from "NTRK Fusion Testing: Ups, Downs of Four Methods" released in the new CAP Today: https://t.co/jslciCLOdv.

[LCM Genect @LCMGenect]

@exosomics_dx @AmoyDx @LCMGenect : on the right track!

[Liquid Biopsy @biopsy_liquid]

Molecular applications of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and exosomes as liquid biopsy for personalized medicine.

#liquidbiopsy #cancer #ctDNA #Oncology
.
📚 Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology

[EACR @EACRnews]

A big thank you to our #LiBi19 exhibitors: @ThermoSciBio @HTGMolecular VyCAP @Parsortix @LCMGenect @SiliconBio @NonacusLtd @promega @Roche @SeraCare. They will all be on the main stage at 14:40 for the Exhibitor Icebreaker Introductions. https://t.co/1KPNhdvAmY

[LCM Genect @LCMGenect]

We are in Bergamo! Look at our stand #ngs #Libi19 #LiquidBiopsies

[LCM Genect @LCMGenect]

-2 days! Wait for you at booth #2 for liquid biopsy news #LiBi19 #liquidbiopsy #precisionmedicine

[LCM Genect @LCMGenect]

Biopsia liquida e oncologia di precisione, grant dalla LILT https://t.co/B2n6BK71Ky

[LCM Genect @LCMGenect]

Giornata mondiale TBC. Ogni giorno 4.400 morti nel mondo. La malattia resta uno dei grandi killer dell’umanità. In Italia 4.000 casi - Quotidiano Sanità https://t.co/Ac3vXGwipZ di @QSanit

[EACR @EACRnews]

NEW SPONSORS 👥: Thank you to ANGLE (@Parsortix), @LCMGenect, @promega, @SeraCare and VyCAP who complete a sold-out exhibition at the EACR-ESMO #LiquidBiopsies conference 2019! #LiBi19 https://t.co/hks65VNWx0

[LCM Genect @LCMGenect]

Oncologia, Fda approva larotrectinib, un farmaco jolly efficace in varie forme di tumore https://t.co/CXZsRcWYBh

[LCM Genect @LCMGenect]

An important step on the road of #precisionmedicine

[Amoy Diagnostics @AmoyDx]

Very excited that the AmoyDx® Essential NGS panel was approved by NMPA on November 20, 2018, for qualitative detection of gene mutations in patients with NSCLC or CRC. It is the first CDx NGS kit approved in China covering different cancer types. PLS SEE https://t.co/gtR8xxW9Dd

[Salute Donna Onlus @Salute_Donna]

Interessante l'intervento del Prof. Antonio Russo, componente del Comitato scientifico di Salute Donna e Salute Uomo